85
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

, , & ORCID Icon
Pages 189-194 | Published online: 18 Jan 2021

References

  • Martin DF, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results: comparison of age-related macular degeneration Treatments Trials (CATT) research. Ophthalmology. 119;2012:1388–1398. doi:10.1016/j.ophtha.2012.03.053
  • Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–1411. doi:10.1016/j.ophtha.2012.04.015
  • Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol two-year results. Ophthalmology. 2016;123:51–59. doi:10.1016/j.ophtha.2015.09.018
  • Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. MARINA: ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. doi:10.1056/NEJMoa054481
  • Brown DM, Michels M, Kaiser PKM, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.
  • Ho AC, Busbee BG, Regillo CD, et al.; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular Degeneration. Ophthalmology. 2014;121:2181–2192. doi:10.1016/j.ophtha.2014.05.009
  • Heier JS, Brown DM, Chong V, et al., VIEW 1 and VIEW 2 Study Groups. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
  • Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127::72–84. doi:10.1016/j.ophtha.2019.04.017
  • Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–1183. doi:10.1016/j.ophtha.2011.12.016
  • Wykoff CC, Croft DE, Brown DM, et al., TREX-AMD Study Group. Prospective Trial of Treat-and-extend versus monthly dosing for neovascular age-related macular degeneration TREX-AMD 1-Year Results. Ophthalmology. 2015;122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009
  • Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON a multicenter cohort Study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299. doi:10.1016/j.ophtha.2013.03.046
  • Bakri SJ, Thorne JE, Ho AC, et al. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the american academy of ophthalmology. Ophthalmology. 2019;126:55–63. doi:10.1016/j.ophtha.2018.07.028